Taken together, the sensitivity of Erenumab and Rimegepant on CGRP evoked responses at CGRP-R and AMY1-R obtained in this study, far exceeds the concentrations required for effective treatment of migraine and inhibition of capsaicin-induced increase of dermal blood flow due to CGRP release. Here, CALCRL is linked to migraine disorder.